3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasm Metastasis
5
Prostatic Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Recurrence
1
Non-Small Cell Lunch Cancer
1
Non Castrate Metastatic Prostate Cancer
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hereditary Sensory and Autonomic Neuropathies
1
Gliosarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Carcinoma, Basal Cell
1
Basal Cell Nevus Syndrome
1
Interventions
Fulvestrant
3
Alpelisib
3
duvelisib
2
Cetuximab
2
volagidemab
1
talazoparib
1
ruxolitinib
1
parsaclisib
1
olaparib
1
obinutuzumab
1
lorlatinib
1
encorafenib
1
dapagliflozin
1
cobimetinib
1
chiauranib
1
binimetinib
1
avelumab
1
Vemurafenib
1
SF 1126
1
Rituximab
1
NVP-BKM120
1
Drug Therapy
1
CYH33
1
Aspirin
1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Hereditary Sensory and Autonomic Neuropathies
×
NVP-BKM120
×
Clear all
NCT01633060
2019-01-30
BELLE-3
Novartis
Phase 3
Terminated
432 enrolled
20 charts